Literature DB >> 24828013

Quantitative assessment of the diagnostic role of human telomerase activity from pancreatic juice in pancreatic cancer.

Siliang Wang1, Xiaodong Chen, Meiyue Tang.   

Abstract

Many studies have shown that human telomerase activity could play potential role as a diagnostic biomarker of pancreatic cancer (PaC). The aim of this meta-analysis is to summarize the clinical value of human telomerase activity in the diagnosis of PaC. Eligible studies from PubMed, Embase, the Cochrane Library, Web of Science, Ovid, Sci Verse, Science Direct, Scopus, BioMed Central, Biosis previews, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP), and Wan Fang databases were searched concerning the diagnostic value of human telomerase activity in PaC without language restriction. The quality of each study was scored with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS). Sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR, respectively), and diagnostic odds ratio (DOR) for human telomerase activity in the diagnosis of PaC were pooled. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance. Evidence of heterogeneity was evaluated using the Chi-square and I (2) test. Meta-Disc 1.4 and Stata 12.0 software were used to analyze the data. Nine studies with a total 186 PaC patients and 132 control individuals were included in this meta-analysis. All of the included studies are of high quality (QUADAS score ≥10). The summary estimate was 0.83 (95 % confidence interval (CI), 95 % CI = 0.77-0.88) for sensitivity and 0.72 (95 % CI = 0.64-0.79) for specificity. The positive likelihood (PLR), negative likelihood (NLR), and diagnostic odds (DOR) ratios were 3 (95 % CI = 1.67-5.41), 0.25 (95 % CI = 0.13-0.46), and 3 (95 % CI = 4.91-43.23), respectively. The area under the summary ROC curve (AUC) and Q* index for the diagnosis of PaC were 0.88 and 0.81, respectively. Our study demonstrates that telomerase could be a useful tumor marker for PaC diagnosis. Although more studies are needed to highlight the theoretical strengths, these results will provide theoretical basis for bringing telomerase activity detection into PaC screening plan.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24828013     DOI: 10.1007/s13277-014-2053-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

2.  Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods.

Authors:  E C Vamvakas
Journal:  Arch Pathol Lab Med       Date:  1998-08       Impact factor: 5.534

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  Advances in pancreatic cancer detection.

Authors:  Cristiana Pistol Tanase; Monica Neagu; Radu Albulescu; Mihail Eugen Hinescu
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

5.  Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification.

Authors:  K Seki; T Suda; Y Aoyagi; S Sugawara; M Natsui; H Motoyama; Y Shirai; T Sekine; H Kawai; Y Mita; N Waguri; T Kuroiwa; M Igarashi; H Asakura
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

Review 6.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

7.  Telomerase activity in small-cell and non-small-cell lung cancers.

Authors:  K Hiyama; E Hiyama; S Ishioka; M Yamakido; K Inai; A F Gazdar; M A Piatyszek; J W Shay
Journal:  J Natl Cancer Inst       Date:  1995-06-21       Impact factor: 13.506

8.  CEACAM1, a novel serum biomarker for pancreatic cancer.

Authors:  Diane M Simeone; Baoan Ji; Mousumi Banerjee; Thiruvengadam Arumugam; Dawei Li; Michelle A Anderson; Ann Marie Bamberger; Joel Greenson; Randal E Brand; Vijaya Ramachandran; Craig D Logsdon
Journal:  Pancreas       Date:  2007-05       Impact factor: 3.327

9.  Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.

Authors:  N Suehara; K Mizumoto; T Muta; Y Tominaga; H Shimura; S Kitajima; N Hamasaki; M Tsuneyoshi; M Tanaka
Journal:  Clin Cancer Res       Date:  1997-06       Impact factor: 12.531

10.  Pancreatitis is a risk factor for pancreatic cancer.

Authors:  P Bansal; A Sonnenberg
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

View more
  1 in total

Review 1.  Telomerase Inhibitors from Natural Products and Their Anticancer Potential.

Authors:  Kumar Ganesan; Baojun Xu
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.